Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial guidance and cost trends related to Medicaid redetermination processes during the specified Class Period [1][4][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, Indiana, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Lawsuit Details - The lawsuit claims that Elevance misled investors by stating they were effectively monitoring cost trends and that premium rates negotiated with states were sufficient to cover rising Medicaid expenses [4]. - It is alleged that the company did not adequately reflect the impact of Medicaid redeterminations, which resulted in a higher utilization of Medicaid members who remained eligible, as those removed were generally healthier [5]. Investor Information - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 7, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - Specific claims include that West was experiencing significant destocking in its high-margin products, contrary to its public statements, and that the SmartDose device was negatively impacting profit margins due to operational inefficiencies [5] - The lawsuit asserts that these misleading statements led to investor damages when the true situation was revealed [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in representing investor interests [4]

LOS ANGELES, June 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) securities between May 2, 2024, to May 6, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR VESTIS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR ...

BENSALEM, Pa., June 18, 2025 /PRNewswire/ -- ­­Law Offices of Howard G. Smith reminds investors of the upcoming August 8, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Vestis Corporation ("Vestis" or the "Company") (NYSE: VSTS) securities between May 2, 2024, to May 6, 2025, inclusive (the "Class Period").IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VESTIS CORPORATION (VSTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECU ...

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR UROGEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER ...

Core Viewpoint - Digimarc Corporation is facing a class action lawsuit due to significant declines in subscription revenue and annual recurring revenue, which were not disclosed to investors during the class period [2][3]. Financial Performance - On February 26, 2025, Digimarc reported a 10% drop in quarterly subscription revenue and a decrease in annual recurring revenue by approximately $2 million, primarily due to a $5.8 million decrease in ARR from a commercial contract expiration in June 2024 [2]. - Following the announcement, Digimarc's stock price fell by $11.65, or 43.1%, closing at $15.39 per share on February 27, 2025 [2]. Lawsuit Details - The class action complaint alleges that Digimarc's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include the failure to disclose that a major commercial partner would not renew a significant contract on the same terms, leading to renegotiation and adverse effects on subscription and annual recurring revenue [3]. Class Action Participation - Investors who purchased Digimarc securities during the class period can file a motion to be appointed as lead plaintiff by July 8, 2025 [4].

Core Viewpoint - The article discusses a class action lawsuit against NET Power Inc. due to significant delays and cost overruns related to its Project Permian, which has negatively impacted the company's stock price and investor confidence [1][6]. Financial Performance and Events - On November 14, 2023, NET Power announced a delay in its Project Permian, pushing the expected operational date from 2026 to between the second half of 2027 and the first half of 2028, citing global supply chain issues [2]. - Following this announcement, NET Power's stock price dropped by $2.47, or 18.5%, closing at $10.85 per share [3]. - On March 10, 2025, the company revealed that the cost estimate for Project Permian had risen significantly, with total installed costs now estimated between $1.7 billion and $2 billion, leading to another stock price decline of $2.18, or 31.5%, closing at $4.75 per share [4]. - On April 15, 2025, the departure of key executives resulted in a further stock price decrease of $0.13, or 5.8%, closing at $2.13 per share [5]. Lawsuit Details - The class action lawsuit alleges that NET Power made materially false and misleading statements regarding the project's timeline and costs, failing to disclose the likelihood of delays and increased expenses due to supply chain issues and other challenges [6]. - Investors who purchased NET Power securities during the class period (June 9, 2023, to March 7, 2025) are encouraged to file a lead plaintiff motion by June 17, 2025 [1][7].

PHILADELPHIA, May 21, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Open Lending Corporation ("Open Lending" or the "Company") (NASDAQ: LPRO) on behalf of purchasers of Open Lending securities between February 24, 2022 through March 31, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Open Lending securities during the Class Period may, no later than JUNE 30, 2025, seek to be appointed as a l ...